Cronos Group Inc. (T:CRON*CA)
Business Focus: Alternative Medicine
| Sector: Healthcare | Industry: Pharmaceuticals |
| Company Contact | |
| Address: | 111 Peter Street, Unit 300 TORONTO ON M5V 2H1 |
| Tel: | N/A |
| Website: | https://thecronosgroup.com |
| IR: | See website |
| Key People | ||
| James Holm Chief Financial Officer | Shannon Buggy Senior Vice President, Global Head of People | John Griese Senior Vice President, Head - Operations (North America) |
| Anna Shlimak Senior Vice President, Corporate Affairs and Strategy | Arye Weigensberg Senior Vice President, Head of Research & Development | Terry Doucet General Counsel and Corporate Secretary |
| Ran Gorelik General Manager, Cronos Israel | Jeffrey David Jacobson Chief Growth Officer | |
| Business Overview |
| Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company's segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company's international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Lord Jones are hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions is a line-up of premium ice water hash infused pre-rolls. Its PEACE NATURALS offers Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Cronos Group Inc revenues increased 1% to $87.2M. Net loss before extraordinary items decreased 55% to $69.8M. Revenues reflect Canada segment increase of 15% to $64.7M, Other countries segment increase from $0K to $1.4M. Lower net loss reflects Impairment loss on other investments decrease of 62% to $23.4M (expense), Interest income, net increase from $22.5M to $51.2M (income). |
| Employees: | 626 as of Dec 31, 2021 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $118.40M as of Dec 31, 2023 |
| Annual revenue (TTM): | $120.07M as of Dec 31, 2023 |
| EBITDA (TTM): | -$99.76M as of Dec 31, 2023 |
| Net annual income (TTM): | -$97.09M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$61.94M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 382,011,178 as of Apr 11, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.